Search
small inhibitory antineoplastic agent (ib drug)
Indications:
- treatment of malignancy
Dosage:
- oral agents
Mechanism of action:
- protein inhibitors, often enzyme inhibitors
Notes:
- other small inhibitory molecules may have actions different from antineoplastic agents
- anacetrapib, evacetrapib, dalcetrapib, torcetrapib (anti-hyperlipidemic agents)
- tofacitinib (DMARD)
- celecoxib, rofecoxib, valdecoxib, parecoxib, etoricoxib, lumiracoxib (COX2 inhibitors)
Related
anacetrapib
celecoxib (Celebrex)
dalcetrapib (JTT-705)
darapladib
etoricoxib (Arcoxia)
evacetrapib
lumiracoxib (Prexige)
parecoxib (Dynastat)
rofecoxib (Vioxx)
tofacitinib (Xeljanz)
torcetrapib
valdecoxib (Bextra)
Specific
abemaciclib (Verzenio)
abrocitinib (Cibinqo)
acalabrutinib (Calquence)
adagrasib (Krazati)
afatinib (Gilotrif)
alectinib (Alecensa)
alisertib (Aurora A kinase inhibitor MLN8237)
alpelisib (Piqray)
asciminib (Scemblix)
avapritinib (Ayvakit)
axitinib (Inlyta)
binimetinib
bortezomib (Velcade)
brigatinib (Alunbrig)
cabozantinib (Cometriq, Cabometyx, XL184)
capivasertib (Truqap)
capmatinib (Tabrecta)
carfilzomib (YU101, CFZ, Kyprolis)
ceritinib; pelitinib (Zykadia)
cobimetinib
copanlisib (Aliqopa)
crizotinib (Xalkori)
dabrafenib (Tafinlar)
dacomitinib (Vizimpro)
dasatinib (Sprycel)
deuruxolitinib (Leqselvi)
duvelisib (Copiktra)
enasidenib (Idhifa)
encorafenib (Mektovi)
entrectinib (Rozlytrek)
erdafitinib (Balversa)
erlotinib (Tarceva)
fedratinib (Inrebic)
filgotinib (Jyseleca)
fostamatinib (Tavalisse)
fruquintinib
futibatinib (Lytgobi)
gefitinib (Iressa)
glasdegib (Daurismo)
ibrutinib (Imbruvica)
idelalisib (Zydelig)
imatinib (Gleevec)
inavolisib (Itovebi)
infigratinib (Truseltiq)
iniparib
ivosidenib (Tibsovo)
ixazomib (Ninlaro)
Janus kinase inhibitor; JAK inhibitor
lapatinib (Tykerb)
larotrectinib
leniolisib (Joenja)
lenvatinib (Lenvima)
lonafarnib (Sarasar)
lorlatinib (Lorbrena)
masitinib (Masican)
mobocertinib (Exkivity)
neratinib (Nerlynx)
nilotinib (Tasigna)
nintedanib; vargatef (Ofev, BIBF-1120)
niraparib (Zejula)
olaparib (Lynparza)
olutasidenib (Rezlidhia)
osimertinib (Tagrisso)
pacritinib (Vonjo)
palbociclib (Ibrance)
pazopanib (Votrient)
pegaptanib
pemigatinib (Pemazyre)
pexidartinib (Turalio)
pirtobrutinib (Jaypirca)
ponatinib (Iclusig)
pralsetinib (Gavreto)
quizartinib (Vanflyta)
regorafenib (BAY 73-4506, Stivarga)
repotrectinib (Augtyro)
revumenib
ribociclib (Kisqali)
ripretinib (Qinlock)
rucaparib (Rubraca)
ruxolitinib (Jakafi, Opzelura)
selpercatinib (Retevmo)
selumetinib (AZD6244)
semaxinib (SU5416)
sonidegib (Odomzo)
sotorasib (Lumakras)
talazoparib (Talzenna)
taselisib
tepotinib (Tepmetko)
tivozanib (Fotivda, AV-951)
toceranib (Palladia)
trametinib (Mekinist)
trilaciclib (Cosela)
tucatinib; irbinitinib (Tukysa)
umbralisib (Ukoniq)
vandetanib (Caprelsa)
veliparib
vemurafenib (Zelboraf, PLX4032)
vismodegib (Erivedge)
vorasidenib (Servier)
zanubrutinib (Brukinsa)
General
antineoplastic agent (chemotherapeutic agent)
References
- My Cancer Genome. Genetically Informed Cancer Medicine.
Overview of Targeted Therapies for Cancer
http://www.mycancergenome.org/content/other/molecular-medicine/overview-of-targeted-therapies-for-cancer/